5 completed, 1 active not recruiting, 1 recruiting. 7 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 4 | Completed 3, Active not recruiting 1 |
Follow Infectious Mononucleosis: new trials by email Literature Review of Infectious Mononucleosis trials Research Report on Infectious Mononucleosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection EBV gp350-ferritin vaccine with ALFQ adjuvant, EBV gH/gL/gp42-ferritin nanoparticle vaccine with ALFQ adjuvant - EBV, Epstein-Barr Virus Infection | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 750 | 2025-05-29 | 2026-10-26 |
| Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator - Epstein-Barr Virus Infection, Infectious Mononucleosis | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 25 | 2023-09-22 | 2026-04-22 |
| A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants mRNA-1195.1, mRNA-1195.2, mRNA-1189 - Epstein-Barr Virus Infection | Phase 1 | Completed | ModernaTX, Inc. | 482 | 2023-04-05 | 2026-11-04 |
| Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults EBV gp350-Ferritin Vaccine - EBV, Epstein-Barr Virus Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 83 | 2022-03-29 | 2026-08-13 |
| A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults mRNA-1189, Placebo - Epstein-Barr Virus Infection | Phase 1 / Phase 2 | Active not recruiting | ModernaTX, Inc. | 867 | 2021-12-28 | 2026-05-06 |
| Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection Valomaciclovir, placebo - Infectious Mononucleosis | Phase 1 / Phase 2 | Completed | University of Minnesota | 23 | 2007-11-01 | 2017-03-22 |
| Controlled Trial of Valacyclovir in Infectious Mononucleosis valacyclovir - Infectious Mononucleosis | Phase 1 / Phase 2 | Completed | University of Minnesota | 20 | 2004-02-01 | 2011-10-27 |
Epstein-Barr Virus Infections (7) · Herpes Simplex (1) · Infections (1) · Virus Diseases (1)
DNA Virus Infections (7) · Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Herpesviridae Infections (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Leukocyte Disorders (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Tumor Virus Infections (7) · Infections (6) · Virus Diseases (6) · Skin Diseases (1) · Skin Diseases, Infectious (1) · Skin Diseases, Viral (1)
Matrix-M (1) · Valacyclovir (1) · valomaciclovir (1)
National Institute of Allergy and Infectious Diseases (NIAID) (3) · ModernaTX, Inc. (2) · University of Minnesota (2)
United States (7)
Jessica R Durkee-Shock, M.D. (3) · Henry H Balfour, MD (2)